-DOCSTART- -X- O
Toll-like -X- _ B-Intervention
receptors -X- _ I-Intervention
( -X- _ I-Intervention
TLRs -X- _ I-Intervention
) -X- _ I-Intervention
comprise -X- _ O
a -X- _ O
clan -X- _ O
of -X- _ O
proteins -X- _ O
involved -X- _ O
in -X- _ O
identification -X- _ O
and -X- _ O
triggering -X- _ O
a -X- _ O
suitable -X- _ O
response -X- _ O
against -X- _ O
pathogenic -X- _ O
attacks. -X- _ O
As -X- _ O
lung -X- _ O
is -X- _ O
steadily -X- _ O
exposed -X- _ O
to -X- _ O
multiple -X- _ O
infectious -X- _ O
agents -X- _ O
, -X- _ O
antigens -X- _ O
and -X- _ O
host-derived -X- _ O
danger -X- _ O
signals -X- _ O
, -X- _ O
the -X- _ O
inhabiting -X- _ O
stromal -X- _ O
and -X- _ O
myeloid -X- _ O
cells -X- _ O
of -X- _ O
the -X- _ O
lung -X- _ O
express -X- _ O
an -X- _ O
aggregate -X- _ O
of -X- _ O
TLRs -X- _ B-Intervention
which -X- _ O
perceive -X- _ O
the -X- _ O
endogenously -X- _ O
derived -X- _ O
damage-associated -X- _ O
molecular -X- _ O
patterns -X- _ O
( -X- _ O
DAMPs -X- _ O
) -X- _ O
along -X- _ O
with -X- _ O
pathogen -X- _ O
associated -X- _ O
molecular -X- _ O
patterns -X- _ O
( -X- _ O
PAMPs -X- _ O
) -X- _ O
and -X- _ O
trigger -X- _ O
the -X- _ O
TLR-associated -X- _ O
signalling -X- _ O
events -X- _ O
involved -X- _ O
in -X- _ O
host -X- _ O
defence. -X- _ O
Thus -X- _ O
, -X- _ O
they -X- _ B-Outcome
form -X- _ I-Outcome
an -X- _ I-Outcome
imperative -X- _ I-Outcome
component -X- _ I-Outcome
of -X- _ I-Outcome
host -X- _ I-Outcome
defence -X- _ I-Outcome
activation -X- _ I-Outcome
in -X- _ I-Outcome
case -X- _ I-Outcome
of -X- _ I-Outcome
microbial -X- _ I-Outcome
infections -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
non- -X- _ I-Outcome
infectious -X- _ I-Outcome
pulmonary -X- _ I-Outcome
disorders -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
interstitial -X- _ I-Outcome
lung -X- _ I-Outcome
disease -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
lung -X- _ I-Outcome
injury -X- _ I-Outcome
and -X- _ I-Outcome
airways -X- _ I-Outcome
disease -X- _ I-Outcome
, -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
COPD -X- _ I-Outcome
and -X- _ I-Outcome
asthma. -X- _ I-Outcome
They -X- _ O
also -X- _ O
play -X- _ O
an -X- _ O
equally -X- _ O
important -X- _ B-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
lung -X- _ I-Outcome
cancer. -X- _ I-Outcome
Targeting -X- _ O
the -X- _ O
TLR -X- _ O
signalling -X- _ O
network -X- _ O
would -X- _ O
pave -X- _ O
ways -X- _ O
to -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
more -X- _ O
reliable -X- _ O
and -X- _ O
effective -X- _ O
vaccines -X- _ O
against -X- _ O
infectious -X- _ O
agents -X- _ O
and -X- _ O
control -X- _ O
deadly -X- _ O
infections -X- _ O
, -X- _ O
desensitize -X- _ O
allergens -X- _ O
and -X- _ O
reduce -X- _ O
inflammation. -X- _ O
Moreover -X- _ O
, -X- _ O
TLR -X- _ O
agonists -X- _ O
may -X- _ O
act -X- _ O
as -X- _ O
adjuvants -X- _ O
by -X- _ O
increasing -X- _ O
the -X- _ O
efficiency -X- _ O
of -X- _ O
cancer -X- _ O
vaccines -X- _ O
, -X- _ O
thereby -X- _ O
contributing -X- _ O
their -X- _ O
role -X- _ O
in -X- _ O
treatment -X- _ O
of -X- _ O
lung -X- _ O
cancer -X- _ O
too. -X- _ O
Overall -X- _ O
, -X- _ O
TLRs -X- _ B-Outcome
present -X- _ I-Outcome
a -X- _ I-Outcome
compelling -X- _ I-Outcome
and -X- _ I-Outcome
expeditiously -X- _ I-Outcome
bolstered -X- _ I-Outcome
area -X- _ I-Outcome
of -X- _ I-Outcome
research -X- _ I-Outcome
and -X- _ I-Outcome
addressing -X- _ I-Outcome
their -X- _ I-Outcome
signalling -X- _ I-Outcome
events -X- _ I-Outcome
would -X- _ I-Outcome
be -X- _ I-Outcome
of -X- _ I-Outcome
significant -X- _ I-Outcome
use -X- _ I-Outcome
in -X- _ I-Outcome
pulmonary -X- _ I-Outcome
diseases -X- _ I-Outcome
. -X- _ O

